The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions by Jördis J Ott et al.
RESEARCH ARTICLE Open Access
The risk of perinatal hepatitis B virus transmission:
hepatitis B e antigen (HBeAg) prevalence
estimates for all world regions
Jördis J Ott*, Gretchen A Stevens and Steven T Wiersma
Abstract
Background: HBeAg presence in childbearing-age women is a major determinant of perinatal hepatitis B virus
(HBV) transmission. The risk of developing chronic HBV infection and liver disease is highest at young age. Our aim
was to assess perinatal HBV transmission risk by means of estimating age- and region-specific HBeAg prevalence.
Methods: Based on observed HBeAg seroprevalence data obtained from a systematic literature review, we
modeled HBeAg prevalence using an empirical Bayesian hierarchical model. Age- and region-specific estimates
were generated for 1990 and 2005.
Results: Globally, highest HBeAg prevalence of over 50% was found in 0–9 years old girls. At reproductive age,
HBeAg prevalence was 20-50%. Prevalence was highest in young females in East Asia in 1990 (78%), the infection
was less common in Sub-Saharan and North Africa. Regional differences in prevalence were smaller in 2005. There
was an overall decrease in HBeAg between 1990 and 2005, which was strongest among girls in Oceania (23.3%
decline), South and South-East Asia (14% decline). However, in these regions, prevalence remained high at 67%
among young females in 2005. Smaller decreases were observed in women at reproductive age, at which 24-32%
of all HBsAg-positive women were HBeAg-positive in 2005, with lowest prevalence in Southern Sub-Saharan Africa
and highest prevalence in Oceania and South-East Asia.
Conclusions: HBeAg estimates are crucial for understanding the epidemiology of HBV and for prioritizing
implementation of WHO`s prevention recommendations for all infants to receive the first dose of hepatitis B
vaccine within 24 hours of birth. Results will have importance as access to treatment for chronic HBV infection is
expanded.
Keywords: Hepatitis B virus, Perinatal transmission, Hepatitis B e antigen (HBeAg), Epidemiology, Prevalence,
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Background
Hepatitis B virus (HBV) is the most serious type of
viral hepatitis causing a potentially life-threatening
liver infection and leading to chronic liver disease
and liver cancer. It is estimated that over two billion
people have been infected with HBV, out of which
360 million individuals are chronically infected [1].
HBV is spread between individuals by contact with
the blood or other body fluids of an infected person.
Perinatal hepatitis B transmission is common in
highly endemic countries and strongly associated
with Hepatitis B "e" antigen (HBeAg) positivity of
childbearing women [1,2]. HBeAg is one of the
serum marker for HBV infection and correlates with
high infectivity. Being a non-structural protein pro-
duced by actively replicating HBV, HBeAg is detect-
able early in the serological course after exposure to
HBV, usually after the first months of infection [1].
The antigen can cross the placental barrier [3], but
almost all perinatal infections occur during delivery
[4]. Studies around the world have confirmed the
high probability of transmission and the increased
risk for chronic HBV infection associated with
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HBeAg-positivity in childbearing women [5-10]. Al-
though both HBsAg-only- and HBsAg-plus HBeAg-
positive persons can transmit the virus to others,
additional HBeAg positivity indicates high viral repli-
cation and infectivity with HBV DNA levels of 107–
109 IU/mL [11,12]. This has implications for the risk of
developing chronic HBV infection: 85% [13] to over 90%
[14] of babies born to HBeAg- positive mothers become
chronic HBV carriers compared to 5% [14] to 31% [13] of
babies born to HBeAg negative, but HBV infected
mothers. The risk is additionally determined by the age at
infection. Where the likelihood of becoming chronically
infected is highest in newborns exposed to HBeAg, it is
about 25-30% in children infected before the age of
5 years and decreases to 5-8% among those infected dur-
ing adulthood [4,15]. The age-dependent risk has a low
likelihood of HBeAg clearance in infancy (<2% per year
below age of 3) that however, increases with age and that
is most common between 15 and 30 years of age [16].
Other factors impacting on HBeAg seroconversion might
be related to geography. Is was shown, for example, that
annual HBeAg- loss occurs at much higher percentage in
the Euro-Mediterranean and African regions as com-
pared to Southeast Asia, where the duration of the
HBeAg positive phase of chronic HBV infection is longer
[17]. This may have implications for the natural history
of chronic HBV infection as well as for HBeAg preva-
lence levels since chronically infected pregnant women
may have a higher proportion of HBeAg positivity. How-
ever, few HBeAg prevalence studies are available with
existing data indicating higher prevalence in HBV hyper-
endemic areas of sub-Saharan Africa and East Asia [6].
Representative regional- and country-specific HBeAg
seroprevalence information is very limited. In contrast to
other markers of HBV such as HBsAg and anti-HBc, no
nationally representative survey reporting on HBeAg is
available and few screening recommendations and prac-
tices are published or implemented. Among the few
countries with national programs to routinely screen
pregnant women for hepatitis B by specifying HBeAg
prevalence are, e.g. the Netherlands [18,19]. All these fac-
tors may contribute to the lack of general awareness
about the importance of this marker for perinatal HBV
transmission as well as to sparse epidemiologic data.
Our goal is to assess HBV perinatal transmission risk
by means of estimating female age-specific HBeAg preva-
lence for 21 world regions based on observed data from a
systematic literature review and subsequent prevalence
modeling. This study is part of the Global Burden of Dis-
ease Study that aims to provide mortality and disease
burden by disease cause and risk factors for 21 world
regions, which are grouped according to child and adult
mortality levels and major causes of death in each coun-
try (Additional file 1: web annex 1) [20].
Methods
The study was carried out in two steps. First, a system-
atic literature review was conducted to collect HBeAg
prevalence data and second, an epidemiological model
was applied to estimate age- and sex-specific HBeAg
prevalence for the 21 world regions (Additional file 1:
web annex 1).
HBeAg prevalence information was identified from a
previously conducted and described systematic review
on hepatitis prevalence [21]. In brief, articles published
between 1980 and 2007 and reporting prevalence of
hepatitis virus infection were systematically searched. A
total of 6064 English citations were found (3273 Med-
line, 2283 Embase, 508 Cinhal). Review articles, outbreak
investigations and national infectious disease notification
reports were excluded. Data reported in the article had
to be reasonably representative of the general population
rather than conducted among a special high-risk group
(i.e. injecting drug users, HIV-positive individuals) or a
population that was selected based on a risk factor for
viral hepatitis or a condition associated with hepatitis
infection.
After applying manual de-duplication and the exclu-
sion criteria on the abstract, 1233 articles on hepatitis B
and C prevalence were obtained (references to studies:
web annex 1 of reference [21], out of which 582
included sero-markers of HBV infection. Most articles
were excluded since they reported HBV markers other
than HBeAg or were conducted among high-risk groups.
Extracted data on HBeAg prevalence among HBsAg
positive individuals were grouped according to 21 Global
Burden of Disease Regions and criteria such as study
population size, sampling procedure and representative-
ness were taken into consideration to rate the quality of
the study. Using the extracted study seroprevalence data,
prevalence of HBeAg was modeled using Dismod III
v3.0, a generic disease modeling system [22], which
models multiple disease parameters, including incidence,
prevalence, remission, and mortality, in order to ensure
consistency among the parameters. Data on each of
these parameters are synthesized using a hierarchical
empirical Bayesian model to make estimates for 21
world regions based on observed data in each modeled
region, data observed in other regions, and data from
other time periods (by estimating a time trend). Briefly,
Dismod III first fits an empirical prior estimate separ-
ately for each disease parameter (e.g., prevalence and in-
cidence). The empirical prior has the following
elements: geographic hierarchy, in which estimates for
each region are informed by data from the same region
and (to a lesser extent) data from other regions; a flex-
ible age pattern; a linear time trend; and an offset for
data on males. Second, for each time period (1980–1997
and 1997-present), sex, and region, Dismod fits a
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Bayesian model using all data in that time-sex-region
group and empirical priors for all epidemiological para-
meters, generating posterior estimates of incidence,
prevalence, remission, and mortality that are internally
consistent. In our model, the empirical priors for inci-
dence, remission, and mortality were uninformative; thus
the posterior was informed only by prevalence data. Like
the empirical prior, the posterior models also incorpor-
ate linear time trends, flexible age patterns, and offsets
for data on males.
Results
69 Articles were identified reporting HBeAg prevalence in-
formation. Most data were available from studies con-
ducted in the high income Asian Pacific region, followed by
Western and Eastern Sub-Saharan Africa, North Africa/
Middle East and Western Europe. No observed data were
found for Latin American regions (Southern, Central,
Andean), for Eastern Europe or for the Caribbean.
Abstracted HBeAg estimates are based on positive cases
among HBsAg carriers and most of the studies were of
cross-sectional nature without any study published pre-
senting nationally representative estimates. Estimated
age-, and year- specific seroprevalence of HBeAg among
female HBsAg- carriers is shown in Table 1 and 2.
Additional prevalence estimates for males are available
from Additional file 1: web annex 2.
Global HBeAg- patterns in 1990
Overall, HBeAg prevalence was clearly age-dependent
with highest rates in the youngest age-group of 0–9 year
old children. In this age-category, over 50% of all HBsAg
positive girls were also HBeAg positive and the rate was
highest in the island states of Oceania and in south-East
Asia, reaching approximately 90% and 80%, respectively.
East Asia, whose prevalence is mainly determined by its
most populous country China, showed HBeAg preva-
lence of 78% in HBsAg positive girls. In contrast, HBeAg
infection was much less common in girls residing in
Western sub-Saharan Africa (56%) and in North Africa
and the Middle East (56%). All other regions had HBeAg
prevalence levels in 0–9 year aged females between 60%
(South Asia including India and Pakistan) and 74% (high
income Asian Pacific regions including Japan, and
Southern Latin America including Argentina, Chile,
Uruguay).
Although most of a decrease of HBeAg is seen across
the younger age-groups, the female 20–39 year age cat-
egory appeared to be affected by high HBeAg prevalence
rates between 20 and 50%. Globally, above 30% of
Table 1 HBeAg prevalence among HBsAg-positive females %, 1990
Region 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Asia Pacific (high income) 74.34 53.09 42.68 32.48 20.40 14.59 15.57 19.26 21.93 22.81
Central Asia 70.04 48.51 36.09 27.52 18.54 14.15 13.25 14.02 15.10 15.56
East Asia 77.80 54.51 40.75 31.04 20.98 16.14 15.03 15.54 16.40 16.82
South Asia 60.55 44.70 33.66 25.61 17.29 13.36 12.54 13.13 14.05 14.46
South East Asia 80.74 55.19 40.39 30.58 20.71 16.04 14.98 15.49 16.39 16.84
Australasia 73.62 51.92 38.12 29.13 20.47 16.31 14.48 13.44 12.63 12.24
Caribbean 68.01 49.09 36.29 27.51 18.64 14.44 13.42 13.83 14.58 14.93
Central Europe 69.54 48.56 36.01 27.46 18.58 14.34 13.50 14.16 15.19 15.67
Eastern Europe 68.35 48.91 36.17 27.46 18.67 14.42 13.37 13.78 14.54 14.90
Western Europe 73.83 49.50 35.82 27.34 18.68 14.53 13.70 14.49 15.59 16.03
Andean LA 68.65 49.11 36.35 27.58 18.74 14.47 13.47 13.97 14.79 15.16
Central LA 68.75 49.15 36.32 27.63 18.79 14.52 13.53 13.99 14.78 15.16
Southern LA 74.81 52.23 38.47 29.23 19.89 15.40 14.31 14.76 15.63 16.09
Tropical LA 67.93 49.20 36.25 27.58 19.03 15.00 13.60 13.26 13.19 13.16
North Africa and Middle East 56.03 41.05 31.32 23.94 16.34 12.71 12.08 12.92 14.05 14.57
North America (high income) 67.08 48.79 36.71 28.07 19.03 14.49 13.49 14.11 15.12 15.63
Oceania 90.59 61.98 43.30 32.14 21.17 16.05 14.95 15.63 16.63 17.08
Central Sub-Saharan Africa 64.19 45.64 33.91 25.80 17.55 13.58 12.61 13.00 13.84 14.28
East Sub-Saharan Africa 70.19 48.90 35.82 26.93 18.02 13.86 12.83 13.29 14.13 14.52
Southern Sub-Saharan Africa 61.79 40.84 30.30 24.05 17.30 13.63 12.69 13.10 13.83 14.16
West Sub-Saharan Africa 55.57 42.20 33.70 26.10 17.80 13.70 12.70 13.23 14.05 14.40
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HBsAg-positive individuals aged< 30 years were also
HBeAg carrier in 1990.
The age-groups 50–69 had the lowest prevalence
which, however, increased at older ages in some areas
such as the high income Asian Pacific regions, Oceania
and South East Asia and, to a lesser extent, in all other
regions, except Australia/New Zealand (Australasia) and
Brazil/Paraguay (Tropical Latin America), which indi-
cated continuous decreases up to the oldest ages.
Global HBeAg- patterns in 2005
Similar to HBeAg prevalence in 1990, the age-pattern of
highest prevalence in children and decreases in adult
age-groups was also seen in 2005. Although reflecting a
decrease in HBeAg prevalence up to 2005, East Asia,
Oceania, and South East Asia remained the regions with
highest prevalence of approximately 67% among 0–9 year
old girls. As in 1990, North Africa and the Middle East
had relatively low HBeAg infection in HBsAg positive
children of about 52%. South Asia showed the lowest
HBeAg prevalence in girls in 2005 (46%) but the
decrease in prevalence between children (0–9 years) and
young adults (10–19 years) was most pronounced in
southern sub-Saharan Africa, which includes South
Africa and in Western Europe. Where the youngest age-
group of southern sub-Saharan Africa had a prevalence
of 55%, HBeAg was prevalent in 36.8% of adolescent
HBsAg carrier. Similar decreases between these age-
groups were obvious in Western Europe (64-41%) and in
the eastern regions of sub-Saharan Africa. Women aged
70 years and older faced small increases in HBeAg
prevalence in all regions, except for tropical Latin
America.
➢ Table 1 and 2, HBeAg prevalence by 10-year age-
group, females, 1990 and 2005
➢ Figure 1 and 2, HBeAg prevalence by 10-year age-
group, females, 1990 and 2005
HBeAg- changes, 1990 and 2005
Differences in female HBeAg prevalence between
regions were less pronounced in 2005 as compared to
1990 and all regions experienced an overall decrease of
HBeAg prevalence up to 2005. In the 0–9 year age-
group, the decrease was strongest in Oceania (23.3%
decline), in South and South-East Asian regions (both
approximately 14% decline). There was no decrease in
the Western sub-Saharan African region that includes
Nigeria and Burkina Faso, where 55% of HBsAg carrier
were HBeAg positive. Relatively small declines in HBeAg
prevalence in the 0–9 year age-group were seen in North
Table 2 HBeAg prevalence among HBsAg-positive females %, 2005
Region 0-9 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-89 90-99
Asia Pacific (high income) 64.44 46.32 34.92 25.63 16.30 12.71 12.95 14.85 17.02 17.98
Central Asia 60.52 43.08 31.78 24.12 16.31 12.53 11.67 12.17 12.98 13.39
East Asia 68.72 49.16 36.10 27.31 18.35 14.01 13.00 13.53 14.51 15.05
South Asia 46.35 35.83 28.20 21.77 14.82 11.42 10.67 11.12 11.81 12.09
South East Asia 66.56 47.73 35.42 26.85 18.10 13.91 13.04 13.66 14.56 14.97
Australasia 64.00 45.86 33.89 25.64 17.38 13.49 12.61 13.08 13.92 14.34
Caribbean 58.69 43.00 31.85 24.14 16.31 12.60 11.78 12.24 13.04 13.45
Central Europe 59.04 42.85 31.91 24.21 16.33 12.55 11.73 12.29 13.13 13.51
Eastern Europe 59.18 42.97 31.87 24.15 16.34 12.64 11.75 12.17 12.89 13.23
Western Europe 63.58 41.39 29.24 22.20 15.61 12.66 12.21 12.90 13.85 14.27
Andean LA 59.42 43.02 31.77 24.08 16.27 12.52 11.70 12.27 13.16 13.54
Central LA 59.11 42.95 31.95 24.26 16.44 12.65 11.74 12.16 12.94 13.34
Southern LA 63.24 45.71 33.89 25.79 17.66 13.74 12.63 12.72 13.08 13.22
Tropical LA 59.85 43.30 31.51 24.08 17.01 13.65 12.06 11.03 10.19 9.79
North Africa and Middle East 52.12 37.62 28.09 21.60 14.98 11.73 11.02 11.41 12.03 12.34
North America (high income) 63.05 45.98 33.91 25.73 17.49 13.47 12.53 12.97 13.74 14.15
Oceania 67.25 47.89 35.66 27.09 18.32 14.11 13.24 13.80 14.53 14.84
Central Sub-Saharan Africa 54.86 40.20 29.98 22.70 15.28 11.73 11.03 11.62 12.44 12.82
East Sub-Saharan Africa 55.50 39.96 30.14 22.96 15.56 12.06 11.22 11.65 12.39 12.72
Southern Sub-Saharan Africa 54.73 36.79 26.90 21.20 15.11 11.87 11.07 11.52 12.30 12.66
West Sub-Saharan Africa 55.32 41.07 30.60 23.17 15.50 11.86 11.06 11.65 12.55 12.95
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Figure 2 HBeAg among HBsAg-positive females, 2005.
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America and North Africa/Middle East (approximately
4% decline).
Decreases in HBeAg prevalence between 1990 and
2005 were smaller in the reproductive age-group of
20–39 year old females and most pronounced in the
Oceania (6% lower in 2005) and high income Asian Paci-
fic regions (7% lower in 2005). Small decreases of only
3% were observed between the time periods in North
Africa/Middle East and North America, respectively. On
a global scale, in 2005, 24-32% of all HBsAg women aged
20–39 years were HBeAg positive with lowest prevalence
in Southern Sub-Saharan Africa and highest prevalence
in Oceania and South East Asia.
➢ Figure 3 and 4
Discussion
Perinatal transmission of HBV is strongly associated
with HBeAg- positivity of childbearing women and im-
plies the highest risk for developing chronic HBV infec-
tion with 85% [13] to over 90% [14] of babies born to
HBeAg positive mothers becoming chronic HBV car-
riers. HBV transmission from HBeAg positive mothers
to newborns is one of the principal transmission routes
of HBV [1,6] and requires comprehensive prevention
strategies such as the implementation of hepatitis B
birth dose administration during the first 24 hours of
life. Hepatitis B prevention by means of immunization
can also reduce the risk of horizontal virus transmission
among children, which might be common in areas such
as Oceania, South East and East Asia, where we found
a particularly high HBeAg prevalence for females aged
0–9 years. The overall high HBeAg prevalence in women
of reproductive age reaching 20-50%, depending on the
region, alludes to the predominance of perinatal HBV
transmission, particularly in countries where hepatitis
birth dose vaccination is not part of routine immunization
schedules. Reductions in HBeAg prevalence among
HBsAg positive women between 1990 and 2005 could be
related to improved hepatitis B vaccination coverage. This
may explain decreases particularly observed in South- and
South East Asian girls (reduction up to 14%). The rela-
tively stable HBeAg prevalence in Sub-Saharan Africa
could thus imply less impact of vaccination and primary
prevention of HBV infection.
Limitations of the study are noted. First, most studies
on HBV seroprevalence have used HBsAg as the bio-
marker for HBV infection and few included information
on HBeAg. This might be associated with limited
resources for HBeAg diagnosis, which leads to an under-
detection of actual prevalence. In addition, several stud-
ies that report HBeAg estimates had to be excluded from
our analysis since they were conducted among high risk
populations or had methodological drawbacks including


































































































































































Figure 3 HBeAg prevalence among HBsAg-positive females by GBD region, 0–9 years, 1990 and 2005.
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partial HBeAg screening of HBsAg positive study sub-
jects [23]. This may lead to an overall underestimation
of HBeAg prevalence. A number of reports and investi-
gations on HBeAg may have been missed by our search,
which did not include unpublished or non-English litera-
ture. Additional data are needed for assessing the poten-
tial heterogeneity of HBeAg prevalence among different
populations within a region.
Limitations of our study include a lack of information
on factors that influence HBeAg seroconversion and
subsequent prevalence. Among these factors are vari-
ables such as ALT levels [24], HIV-infection [25], and
age [16]. HBV genotype has also been shown to be sig-
nificantly associated with both HBeAg seropositivity and
HBeAg seroconversion rates: HBV genotype B patients
are known to have higher rates of seroconversion than
those with genotype C infections, making genotype B an
independent predictor of HBeAg seroconversion [26-28].
Additionally, a higher HBeAg seropositivity rate was
demonstrated for genotype C carriers compared to geno-
type B carriers [25]. In another study, it was shown that
mean age of HBeAg seroconversion was over 40 years
among those infected with genotype C compared to less
than 20 years among those infected with other HBV gen-
otypes [29], which makes the prevention of perinatal
transmission particular important for countries with
high genotype C prevalence.
HBeAg seropositivity may also be more common
among genotype E infected persons compared to geno-
type A infected patients, as preliminary data indicate
[30]. With regard to subgenotypes, HBeAg appeared to
be significantly less frequent in HBV/Aa carriers than in
HBV/Ae carriers (below age of 30 years) [31]. Despite
the significance of genotype information for HBeAg
prevalence, seroconversion and perinatal transmission
risk, this information is rarely available from sero-epi-
demiological studies.
The strengths of our study are related to the extensive
systematic review that was conducted for a 27 year period,
and the use of a flexible Bayesian model to estimate
HBeAg prevalence. In previous reviews and epidemio-
logical studies, HBeAg has deserved less attention as a
marker of HBV infection, although this biomarker of high
viral load is highly significantly associated with HCC risk
[32,33], and could further explain geographical differences
in liver cancer incidence.
Conclusions
Perinatal HBV transmission is a major determinant of
HBV carrier status and its chronic sequelae, and maintains
HBV transmission across generations. HBeAg prevalence
estimates provided from this study are an important com-
ponent for assessing the HBV- related disease burden and
its economical and medical consequences. In addition,


































































































































































Figure 4 HBeAg prevalence among HBsAg-positive females by GBD region, 20–39 years, 1990 and 2005.
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HBeAg epidemiology is of relevance as access to treat-
ment for chronic HBV infection is expanded with increas-
ing treatment options in resource-limited settings [34].
The information provided will be useful in prioritizing the
implementation of WHO`s perinatal hepatitis B preven-
tion recommendation for all infants to receive the birth
dose of hepatitis B vaccine during the first 24 hours of life
[1]. As HbeAg testing is not available in many areas of the
world and since routine screening is not economically
feasible and cost-effective in all settings [35-37], preven-
tion remains to be the method for eliminating perinatal
transmission of HBV and can contribute to a decrease of
chronic HBV infection and its sequelae.
Additional file
Additional file 1: Web annex.
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